Partnering and Collaborations

4SC is focused on developing targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer. Through development partnerships with pharmaceutical and biotech companies as well as academia and clinics, we are bringing our programs closer to market approval, and ultimate commercial success.

For our core products resminostat, 4SC-202 and 4SC-208 we are open for partnering or collaborations with:

  • Pharmaceutical companies to support clinical development after Proof of Concept and/or to commercialize products after completing regulatory filings
  • Investigators and clinical sites interested in performing investigator sponsored trials / research with our products as monotherapy or in combination to improve existing therapies in cancer
  • Biotech and Pharmaceutical companies to develop novel assets in synergy with our epigenetic product pipeline
  • Academia to support our pre-clinical efforts

If you are interested in collaborating with 4SC, please email hidden; JavaScript is required.

Partners and licensees

Share this page:

Follow us on: